(Total Views: 291)
Posted On: 01/19/2023 1:15:46 PM
Post# of 76

$JAZZ News Article - Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma https://marketwirenews.com/news-releases/jazz...79936.html


My Twitter: WhyteStocks